Glisoxepid or glisoxepide

This classification denotes an anti-diabetic agent with the molecular formula C20H27N5O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H7SC0I332I, chemically known as 3-isoxazolecarboxamide, n-(2-(4-(((((hexahydro-1h-azepin-1-yl)amino)carbonyl)amino)sulfonyl)phenyl)ethyl)-5-methyl- but more generally known as glisoxepid, which bears US NIH Compound Identifier 32778. European Medicines Agency schedules Glisoxepide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07933MIG. The term GLISOXEPIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 25 , No. 10 1971, List 11) WHO schedules glisoxepid in its Anatomical Therapeutic Chemical (ATC) Classification. Glisoxepid or glisoxepide bears US NLM identifiers UMLS ID C0061330 and NCI Concept Code C72801. SMILES: CC1=CC(=NO1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NN3CCCCCC3.